



ASX ANNOUNCEMENT

Doug Ward Appointed To Board As Managing Director

MELBOURNE, Australia (13 July 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to announce its Chief Executive Officer, Doug Ward, has been appointed to Lumos Diagnostics’ Board of Directors as Managing Director.

Doug Ward was appointed and commenced as CEO of Lumos in June 2022. Doug has over 30 years experience as an executive in the diagnostics and healthcare industries. He joined from his previous role at the leading US women’s healthcare company, Hologic. Prior to this, Doug was CEO of PDGX, a genomics *in vitro* diagnostics company that was acquired by LabCorp in 2022 for US\$575 million. Since his appointment, Doug has played a key role in the restructuring and refocusing of Lumos, as well as managing FebriDx through the recent FDA clearance following its rejection last year.

“We are delighted to welcome Doug onto Lumos Diagnostics Board of Directors,” said Sam Lanyon, Chair of Lumos. “Doug’s experience and contribution as CEO of Lumos has been both impressive and invaluable, and we look forward to further benefitting from these as a Board with his appointment as Managing Director”.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598